title: Mechanism of antiarrhythmic action of beta-blocking agents.
abstract: We investigated the antiarrhythmic effect of beta-blocking agents. Using 35 anesthetized dogs, the chest was opened and the left anterior descending coronary artery (LAD) was ligated for 30 min and the ventricular multiple response threshold (VMRT) was observed in the time course. The dogs were divided into five groups premedicated intravenously ten min before LAD ligation with either isotonic saline (the control group), D,L-propranolol (0.5 mg/kg), D-propranolol (0.5 mg/kg), D,L-pindolol (0.1 mg/kg), or D,L-acebutolol (2.5 mg/kg). Thirty min after ligation, myocardial mitochondria were prepared from the ischemic and the non-ischemic areas, and then the content of mitochondrial long-chain acyl-CoA and Ca++-binding activity were measured. The value of VMRT 1.59 +/- 0.21 mA before ligation decreased to 0.99 +/- 0.13 mA 30 min after ligation. Content of acyl-CoA in mitochondria from the ischemic area increased significantly compared to those from the non-ischemic area. Mitochondrial Ca++-binding activity in the ischemic area decreased significantly compared to that in the non-ischemic area. Each administration of three beta-blocking agents prevented the decreases in VMRT and Ca++-binding activity and excessive accumulation of acyl-CoA; D-propranolol had no effect. These results suggest that the antiarrhythmic action of beta-blocking agents is based, at least in part, on the protection from decrease in Ca++-binding activity due to mitochondrial dysfunction induced by the excessive accumulation of long-chain acyl-CoA in mitochondria.
authors.forename: S
authors.initials: S
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Hattori
authors.forename: Y
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: S
authors.initials: S
authors.lastname: Nagai
authors.forename: T
authors.initials: T
authors.lastname: Ozawa
mesh_terms: D000070:Acebutolol / Q000627:therapeutic use; D000214:Acyl Coenzyme A / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002118:Calcium / Q000378:metabolism; D002304:Cardiac Pacing, Artificial; D003331:Coronary Vessels / Q000601:surgery; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D008026:Ligation; D008297:Male; D008929:Mitochondria, Heart / Q000378:metabolism; D010869:Pindolol / Q000627:therapeutic use; D011292:Premedication; D011433:Propranolol / Q000627:therapeutic use
chemical_list: D000214:Acyl Coenzyme A; D000319:Adrenergic beta-Antagonists; D000070:Acebutolol; D011433:Propranolol; D010869:Pindolol; D002118:Calcium